New antibody joins fight against tough lung cancers

NCT ID NCT07246863

Summary

This study is testing whether adding a new antibody drug called visugromab to standard treatments helps control advanced non-small cell lung cancer that has worsened after initial therapy. It will compare different combinations of visugromab, an immunotherapy drug (nivolumab), and chemotherapy (docetaxel) against chemotherapy alone. The main goal is to see if these combinations shrink tumors and extend life for people who have already tried one prior treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cantonal Hospital Saint Gallen, Clinic of Oncology and Hematology

    RECRUITING

    Sankt Gallen, CH-9007, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Duke University Medical Center

    NOT_YET_RECRUITING

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Basel

    RECRUITING

    Basel, 4031, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital of Jaen

    RECRUITING

    Jaén, Andalusia, 23007, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)

    NOT_YET_RECRUITING

    Birmingham, Alabama, 35294-3300, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.